Latest Clinical News

Cancer Connect Launches On line Community for Patients with Neuroendocrine Tumors (02-23-2017)

Sun Valley ID & Austin TX— OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect for individuals with neuroendocrine tumors (NET). This community will provide patients and their loved ones with information and... Continue Reading

Unique Gene Signature Predicts Potentially Lethal Prostate Cancers (02-23-2017)

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of... Continue Reading

Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth (02-22-2017)

A troublesome side effect of radiation therapy treatment of cancers involving the head and neck is dry mouth.  This occurs as a consequence of radiation damage to the salivary glands.  According to a new study, changing the intensity of radiotherapy... Continue Reading

Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome (02-21-2017)

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation... Continue Reading

Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated! (02-20-2017)

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer no immediate consequences, but years later have... Continue Reading

Proton beam therapy may improve outcomes for pancreatic cancer (02-17-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

FDA Approves Opdivo for Treatment of Bladder Cancer (02-16-2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading

Vaccine Shows Promising Results for Early-Stage Breast Cancer Patients (02-15-2017)

Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient’s own immune system to fight and kill cancer. Doctors at Moffitt Cancer Center in Tampa Florida are working on a promising new vaccine that... Continue Reading

Twice-daily radiation therapy reduces mortality from head and neck cancer (02-14-2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading

Imbruvica® is approved by FDA for Marginal Zone Lymphoma (02-7-2017)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. These data were... Continue Reading

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer (02-6-2017)

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer... Continue Reading

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (02-3-2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were published in The Lancet Oncology, and presented at... Continue Reading

Next Page »